We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

38 hedge funds and large institutions have $49.7M invested in F-star Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

22% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 9

9% more funds holding

Funds holding: 35 → 38 (+3)

14% less capital invested

Capital invested by funds: $57.7M → $49.7M (-$8.03M)

Holders
38
Holders Change
+3
Holders Change %
+8.57%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
11
Reduced
9
Closed
6
Calls
$2.69M
Puts
–
Net Calls
+$2.69M
Net Calls Change
-$680K

Top Buyers

Rank Fund Capital Flow
1
TA
Tiedemann Advisors
New York
+$6.13M
2
BI
BVF Inc
California
+$2.54M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.18M
4
IBT
International Biotechnology Trust
United Kingdom
+$1.09M
5
Millennium Management
Millennium Management
New York
+$748K

Top Sellers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
-$4.2M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.1M
3
SFM
Sphera Funds Management
Israel
-$1.27M
4
EI
EAM Investors
California
-$718K
5
Renaissance Technologies
Renaissance Technologies
New York
-$571K
Name Holding Trade Value Shares
Change 		Change in
Stake
WSFS
26
Wilmington Savings Fund Society
Delaware
$188K – – –
VF
27
Virtu Financial
New York
$172K +$190K +3,197 New
SQA
28
Simon Quick Advisors
New Jersey
$149K +$81.8K +1,375 +85%
Wells Fargo
29
Wells Fargo
California
$101K +$112K +1,877 New
Deutsche Bank
30
Deutsche Bank
Germany
$100K -$351K -5,900 -76%
Barclays
31
Barclays
United Kingdom
$75K +$83.3K +1,400 New
GT
32
Glenmede Trust
Pennsylvania
$55K +$62K +1,042 New
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$29K +$30.2K +507 +1,127%
UBS Group
34
UBS Group
Switzerland
$22K -$5.95K -100 -20%
EWM
35
Evercore Wealth Management
New York
$13K – – –
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$7K -$952 -16 -11%
LTFS
37
Ladenburg Thalmann Financial Services
Florida
$7K – – –
TRCT
38
Tower Research Capital (TRC)
New York
$1K -$1.84K -31 -62%
RI
39
RTW Investments
New York
– -$4.2M -62,274 Closed
EI
40
EAM Investors
California
– -$718K -10,666 Closed
Renaissance Technologies
41
Renaissance Technologies
New York
– -$571K -8,471 Closed
EC
42
EcoR1 Capital
California
– -$269K -4,000 Closed
DCM
43
DAFNA Capital Management
California
– -$110K -1,627 Closed
TDC
44
Thompson Davis & Co
Virginia
– -$22K -325 Closed
1
2

FSTX Hedge Fund Activity: Q4 2017 in Review

38 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q4 2017, worth a combined $49.7M — down 14% from $57.7M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new FSTX positions and 6 closed out — a net gain of 3 holders — while 11 added to existing stakes and 9 trimmed.

The largest buyer was Tiedemann Advisors, opening a new position worth an estimated $6.13M. The largest seller was RTW Investments, exiting entirely with an estimated $4.2M sold.

  • 38 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q4 2017, up from 35 in Q3 2017.
  • Funds reported $49.7M of F-star Therapeutics, Inc. Common Stock stock for Q4 2017, down 14% quarter-over-quarter.
  • 9 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q4 2017 and 6 closed out, a net change of +3 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q4 2017 was Tiedemann Advisors, an estimated $6.13M added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q4 2017 was RTW Investments, an estimated $4.2M sold.

Based on aggregated 13F filings for Q4 2017.